Loading organizations...
§ Private Profile · New Haven, CT, USA
Clinical-stage biotechnology firm developing alphalex™ PDC therapeutics for oncology, targeting breast, ovarian, and lung cancers.
Based in New Haven, Connecticut, Cybrexa Therapeutics is a clinical-stage biotechnology company that develops antigen-independent tumor-targeting peptide drug conjugate therapeutics for cancer treatment. The firm utilizes its proprietary alphalex technology platform to facilitate the intracellular delivery of potent anticancer agents directly into tumor cells. Its primary clinical pipeline centers on developing oncology drugs to treat patients suffering from breast, ovarian, and non-small cell lung cancers. Operating as a privately held enterprise, the organization has successfully raised more than $47 million in venture capital funding to advance its ongoing clinical trials and research. Cybrexa is currently backed by a syndicate of institutional investors that includes Advantage Capital Connecticut, Connecticut Innovations, Elm Street Ventures, and HighCape Capital. The biotechnology company was founded in 2017 by chief executive officer Per Hellsund alongside a dedicated team of scientific co-founders.
Cybrexa Therapeutics has raised $44.4M across 3 funding rounds.
Cybrexa Therapeutics has raised $44.4M in total across 3 funding rounds.
Cybrexa Therapeutics has raised $44.4M in total across 3 funding rounds.
Cybrexa Therapeutics's investors include Elm Street Ventures, Kevin Rakin, Connecticut Innovations, Cycle Venture Partners, HighCape Capital.
Cybrexa Therapeutics has raised $44.4M across 3 funding rounds. Most recently, it raised $25.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 11, 2021 | $25M Series B | — | ELM Street Ventures, Kevin Rakin | Announced |
| Jun 20, 2019 | $13.4M Series B | — | Connecticut Innovations, Cycle Venture Partners, Highcape Capital | Announced |
| Jun 16, 2017 | $6M Series B | — | Connecticut Innovations, Highcape Capital | Announced |